Arcturus Therapeutics Holdings (ARCT) Change in Account Payables (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) posted Change in Account Payables of -$142000.0 for Q1 2026, up 89.43% on a QoQ basis from -$1.3 million in Q4 2025, and up 86.01% year-over-year from -$76340.0 in Q1 2025.
Arcturus Therapeutics Holdings (ARCT) Change in Account Payables (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings' Change in Account Payables history runs 9 years deep, the most recent figure standing at -$142000.0 for Q1 2026.
- Quarterly Change in Account Payables rose 86.01% year-over-year to -$142000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.1 million (up 29.65% YoY) and the FY2025 annual result came in at -$3.0 million, down 254.52% from the prior year.
- Change in Account Payables was -$142000.0 for Q1 2026 at Arcturus Therapeutics Holdings, up from -$1.3 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $11.8 million in Q1 2023 and bottomed at -$12.7 million in Q4 2023.
- A 5-year average of -$384470.6 and a median of -$1.0 million in 2025 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables plunged 569.28% — and 2023, when it surged 26890.91%.
- Arcturus Therapeutics Holdings' Change in Account Payables stood at -$8.4 million in 2022, then sank by 50.76% to -$12.7 million in 2023, then soared by 76.94% to -$2.9 million in 2024, then soared by 54.27% to -$1.3 million in 2025, then jumped by 89.43% to -$142000.0 in 2026.
- Business Quant data shows ARCT's Change in Account Payables at -$142000.0 in Q1 2026, -$1.3 million in Q4 2025, and -$5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Arcturus Therapeutics Holdings | 164.57 Mn | -46.81 Mn | - | -142,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -142,000.00 |
| Mar 31, 2026 | -142,000.00 |
| Dec 31, 2025 | -1.34 Mn |
| Dec 31, 2025 | -1.34 Mn |
| Sep 30, 2025 | -5.05 Mn |
| Sep 30, 2025 | -5.05 Mn |
| Jun 30, 2025 | 4.44 Mn |
| Jun 30, 2025 | 4.44 Mn |
| Mar 31, 2025 | -1.02 Mn |
| Mar 31, 2025 | -1.02 Mn |
| Dec 31, 2024 | -2.94 Mn |
| Dec 31, 2024 | -2.94 Mn |
| Sep 30, 2024 | -3.77 Mn |
| Sep 30, 2024 | -3.77 Mn |
| Jun 30, 2024 | 4.76 Mn |
| Jun 30, 2024 | 4.76 Mn |
| Mar 31, 2024 | 3.87 Mn |
| Mar 31, 2024 | 3.87 Mn |
| Dec 31, 2023 | -12.74 Mn |
| Dec 31, 2023 | -12.74 Mn |